Please login to the form below

Not currently logged in
Email:
Password:

CGRP inhibitors

This page shows the latest CGRP inhibitors news and features for those working in and with pharma, biotech and healthcare.

Amgen CEO says Aimovig is “one of most successful launches”

Amgen CEO says Aimovig is “one of most successful launches”

The company estimates that more than 100, 000 patients have taken the Novartis-partnered CGRP inhibitor since its launch in May as a once-monthly, self-injected preventive treatment for migraines. ... The strong take-up has come despite approvals for

Latest news

  • Teva wins FDA OK for crucial migraine drug Teva wins FDA OK for crucial migraine drug

    analysts to predict buoyant sales of the CGRP inhibitors. ... the injectable CGRP inhibitors.

  • CGRP migraine drugs need prior approval for use, recommends ICER CGRP migraine drugs need prior approval for use, recommends ICER

    Suggests clinicians should confirm that patients have tried other therapies prior to using CGRP inhibitors. ... The Institute for Clinical and Economic Review (ICER) is recommending that insurers introduce “evidence-based prior authorisation

  • The year of the blockbuster The year of the blockbuster

    Drugs to watch in 2018. Aimovig (erenumab) from Amgen and Novartis:Migraine prevention is about to undergo a transformation with several novel calcitonin gene-related peptide (CGRP) receptor inhibitors likely gaining ... from two similar drugs targeting

  • ICER says price of Amgen/Novartis’ Aimovig is OK - if used last-line ICER says price of Amgen/Novartis’ Aimovig is OK - if used last-line

    An earlier analysis by the organisation, which used a model price of $8, 500 per year, concluded that CGRP inhibitors would be too expensive at that level. ... As migraine is common, “there may be concerns about affordability and access [and] CGRP

  • Novartis, Amgen set low price for first CGRP migraine drug Novartis, Amgen set low price for first CGRP migraine drug

    Aimovig has a list price of $6, 900 per year. Amgen and Novartis have claimed the first approval for a CGRP inhibitor in migraine, getting an FDA green light for their ... The premium over older drugs for prevention should be supportable given that some

More from news
Approximately 2 fully matching, plus 8 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health Communications

Formerly known as Packer Forbes Communications, Four Health Communications is an award-winning, integrated healthcare communications agency for pharma, biotech, NGOs...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics